Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 12.28B 10.71B 10.11B 9.18B 17.2B 1,178B 17.27B 121B 46.74B 599B 46.13B 45.11B 1,928B P/E 2026 *
-84.2x
P/E 2027 * 84.4x
Enterprise Value 11.76B 10.25B 9.68B 8.79B 16.47B 1,128B 16.54B 116B 44.74B 574B 44.16B 43.18B 1,845B EV / Sales 2026 *
7.7x
EV / Sales 2027 * 5.29x
Free-Float
94.17%
Yield 2026 *
-
Yield 2027 * -
1 day-0.54%
1 week-0.56%
Current month-1.58%
1 month+1.36%
3 months+5.10%
6 months+20.25%
Current year-8.73%
1 week 513.36
Extreme 513.36
541.34
1 month 506.29
Extreme 506.29
552.08
Current year 416.21
Extreme 416.21
598.79
1 year 393.6
Extreme 393.605
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 10
Extreme 10
615
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Date Insider Type Main position Quantity % Market Cap. Importance
11/9/26 Sell

Chief Executive Officer

-5,221 0.0226%
17/8/26 Sell

General Counsel

-664 0.0029%
15/8/26 Free

Director

1,725 0.0075%
Change 5-day change 1-year change 3-year change Capi.($)
-0.54%-0.56%+20.59%+224.93% 12.28B
-0.31%+5.79%+48.93%+97.53% 70.88B
+0.39%+2.06%+40.91%+78.49% 62.49B
-3.21%-7.27%-17.73%+351.98% 26.21B
+0.50%+7.13%+29.43%+15.48% 26.34B
-2.64%-0.69%-0.26%-11.90% 24.13B
+0.71%+8.03%+27.22%-13.18% 20.72B
-1.26%-7.81%+169.33%+302.38% 15.36B
-0.22%+3.99%+44.28%+173.35% 14.46B
+0.73%+1.71%-7.18%+886.19% 14.25B
Average -0.58%+1.43%+35.55%+210.52% 28.71B
Weighted average by Cap. -0.47%+1.35%+35.83%+151.27%

Financials

2026 *2027 *
Net sales 1.53B 1.33B 1.26B 1.14B 2.14B 146B 2.15B 15.05B 5.81B 74.46B 5.73B 5.61B 240B 2.14B 1.87B 1.77B 1.6B 3B 206B 3.02B 21.15B 8.16B 105B 8.06B 7.88B 337B
Net income -184M -160M -151M -137M -258M -17.64B -259M -1.81B -700M -8.97B -691M -675M -28.86B 200M 174M 165M 150M 280M 19.19B 281M 1.97B 761M 9.76B 751M 735M 31.39B
Net Debt -525M -457M -432M -392M -735M -50.33B -738M -5.17B -2B -25.59B -1.97B -1.93B -82.33B -943M -822M -777M -705M -1.32B -90.51B -1.33B -9.3B -3.59B -46.01B -3.54B -3.46B -148B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
18/09/26 US$531.52 -0.54% 330,617
17/09/26 US$534.40 +1.00% 153,313
16/09/26 US$529.09 +1.11% 298,474
15/09/26 US$523.26 -3.11% 259,412
14/09/26 US$540.06 +1.04% 156,535
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
531.52USD
Average target price
678.06USD
Spread / Average Target
+27.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!